Beverly J Lange
Affiliation: The Children's Hospital of Philadelphia
- The old grey mare, she ain't what she used to be. Is she?: (commentary on Kaspers et al., page 539)Beverly Lange
Pediatric Oncology, Children s Hospital of Philadelphia, Philadelphia, Pennsylvania 19003, USA
Pediatr Blood Cancer 47:535-6. 2006
- Soluble interleukin-2 receptor α activation in a Children's Oncology Group randomized trial of interleukin-2 therapy for pediatric acute myeloid leukemiaBeverly J Lange
The Children s Hospital of Philadelphia, Philadelphia, PA, USA
Pediatr Blood Cancer 57:398-405. 2011..To assess associations of soluble IL-2 receptor alpha (sIL-2rα) concentration with outcomes in pediatric acute myeloid leukemia (AML) in a phase 3 trial of IL-2 therapy...
- Outcomes in CCG-2961, a children's oncology group phase 3 trial for untreated pediatric acute myeloid leukemia: a report from the children's oncology groupBeverly J Lange
University of Pennsylvania School of Medicine and The Children s Hospital of Philadelphia, Division of Oncology, Philadelphia, PA, USA
Blood 111:1044-53. 2008..No new agent improved outcomes; experience may have contributed to better results time...
- Mortality in overweight and underweight children with acute myeloid leukemiaBeverly J Lange
Division of Oncology, The Children s Hospital of Philadelphia, Philadelphia, PA 19104, USA
JAMA 293:203-11. 2005..Overweight children with AML seem to experience excess life-threatening and fatal toxicity. Nothing is known about how weight affects outcomes in pediatric AML...
- Double-delayed intensification improves event-free survival for children with intermediate-risk acute lymphoblastic leukemia: a report from the Children's Cancer GroupBeverly J Lange
Division of Oncology, Children s Hospital of Philadelphia, PA, USA
Blood 99:825-33. 2002..These data demonstrate that DDI improves EFS of patients younger than 10 years of age with intermediate-risk ALL...
- Safety and efficacy of gemtuzumab ozogamicin in combination with chemotherapy for pediatric acute myeloid leukemia: a report from the Children's Oncology GroupRichard Aplenc
Children s Hospital of Philadelphia, Center for Clinical Epidemiology Biostatistic, 3615 Civic Center Blvd, 916G ARC, Philadelphia, PA 19104 4318, USA
J Clin Oncol 26:2390-3295. 2008....
- Pilot study of idarubicin-based intensive-timing induction therapy for children with previously untreated acute myeloid leukemia: Children's Cancer Group Study 2941Beverly J Lange
Children s Hospital of Philadelphia, Philadelphia, PA, USA
J Clin Oncol 22:150-6. 2004..In Children's Cancer Group Pilot Study CCG-2941, we assessed toxicity and feasibility of substituting 4 mg of DNR with 1 mg of IDA in intensive-timing daunorubicin-based induction therapy (DNR/DNR) used in CCG-2891...
- Ethnicity and survival in childhood acute myeloid leukemia: a report from the Children's Oncology GroupRichard Aplenc
Pediatric Oncology, University of Pennsylvania, Philadelphia, PA 19104, USA
Blood 108:74-80. 2006..Fewer black children than expected had an available family marrow donor...
- Bone-marrow relapse in paediatric acute lymphoblastic leukaemiaL Charles Bailey
Division of Oncology, Children s Hospital of Philadelphia, and University of Pennsylvania School of Medicine, Philadelphia, PA, USA
Lancet Oncol 9:873-83. 2008..Although better drugs are needed, introduction of new agents into clinical trials in paediatric disease has been difficult. Innovative trial designs and use of valid surrogate endpoints may expedite this process...
- Factitious fungus in two children with cancer receiving liposomal amphotericinMichael J Fisher
Department of Pediatrics, Children s Hospital of Philadelphia, Pennsylvania 19104, USA
J Pediatr Hematol Oncol 24:360-3. 2002..These cases underscore the importance of establishing a microbiologic diagnosis in cases of presumed fungal infection...
- Identifying psychosocial risk indicative of subsequent resource use in families of newly diagnosed pediatric oncology patientsAnne E Kazak
Division of Oncology, The Children s Hospital of Philadelphia, Room 1486 CHOP North, 34th St and Civic Center Blvd, Philadelphia, PA 19104, USA
J Clin Oncol 21:3220-5. 2003..Additional study aims were to examine concordance among family and staff reports of psychosocial risk, changes in risk status over time, and to predict the use of psychosocial resources during the first months of treatment...
- Evolving concepts of management of febrile neutropenia in children with cancerElmar Orudjev
Division of Oncology, The Children s Hospital of Philadelphia, The University of Pennsylvania, School of Medicine, Philadelphia, Pennsylvania 19104, USA
Med Pediatr Oncol 39:77-85. 2002..Recent investigations of febrile neutropenia in pediatric cancer patients have identified subsets of low-risk patients who can be managed with less antibiotic therapy than previously recommended standards...
- Infections with viridans group streptococci in children with cancerAnne F Reilly
Division of Oncology, Department of Pediatrics, The Children s Hospital of Philadelphia, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
Pediatr Blood Cancer 49:774-80. 2007..Routine systemic antimicrobial prophylaxis against VGS infection has not been proven effective. Current recommendations include appropriate antibiotic therapy and intensive supportive care...
- Central nervous system juvenile xanthogranuloma with malignant transformationAndrea Orsey
Division of Pediatric Oncology, Children s Hospital of Philadelphia, Philadelphia, Pennsylvania, USA
Pediatr Blood Cancer 50:927-30. 2008..Despite further chemotherapy, the patient died of disease progression. This case highlights the clinical and pathological heterogeneity of JXG and the difficulty of treating multi-focal CNS disease...
- Isolated extramedullary relapse in acute myeloid leukemia: A retrospective analysisJill P Ginsberg
Division of Oncology, The Children s Hospital of Philadelphia, Department of Pediatrics, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA
Med Pediatr Oncol 38:387-90. 2002..Little is known about the characteristics and outcome of children with acute myeloid leukemia (AML) experiencing an isolated extramedullary relapse (IEMR)...
- Amifostine for children with medulloblastoma treated with cisplatin-based chemotherapyMichael J Fisher
Division of Oncology, The Children s Hospital of Philadelphia, Philadelphia, Pennsylvania 19104, USA
Pediatr Blood Cancer 43:780-4. 2004..Larger studies will help clarify these findings...
- Long-term (15 years) outcome in an infant with metastatic adrenocortical carcinomaDiva D De Leon
Division of Endocrinology, Department of Pediatrics, Children s Hospital of Philadelphia, Philadelphia, Pennsylvania 19104, USA
J Clin Endocrinol Metab 87:4452-6. 2002..His motor and speech development was delayed. After mitotane was discontinued he demonstrated catch-up growth. This case shows successful long-term outcome and recovery from the toxic effects of mitotane...
- CYP3A genotypes and treatment response in paediatric acute lymphoblastic leukaemiaRichard Aplenc
Children s Hospital of Philadelphia, Philadelphia, University of Pennsylvania, PA, Children s Cancer Study Group, Arcadia, CA, USA
Br J Haematol 122:240-4. 2003..CYP3 genotypes may not significantly modify the risk of relapse in childhood ALL, but may modify the risk of toxicity...
- Pharmacogenetic determinants of outcome in acute lymphoblastic leukaemiaRichard Aplenc
Department of Pediatrics, The Children s Hospital of Philadelphia, Philadelphia, PA 19104, USA
Br J Haematol 125:421-34. 2004..This review summarizes current research on the impact of genetic variation in drug-processing genes in paediatric ALL and reviews important methodological and statistical issues presently challenging the field of pharmacogenetics...
- Methylenetetrahydrofolate reductase polymorphisms and therapy response in pediatric acute lymphoblastic leukemiaRichard Aplenc
Children s Hospital of Philadelphia, PA 19104, USA
Cancer Res 65:2482-7. 2005..These data provide evidence that the MTHFR C677T polymorphism is a common genetic variant conferring a moderate relative risk and a high attributable risk for relapse in pediatric ALL patients...
- Clinical implications of FLT3 mutations in pediatric AMLSoheil Meshinchi
Fred Hutchinson Cancer Research Center, Clinical Research Division, D5 380, 1100 Fairview Ave N, Seattle, WA 98103, USA
Blood 108:3654-61. 2006..001) or with FLT3/WT (55%, P < .001). ITD-AR defines the prognostic significance in FLT3/ITD-positive AML, and ITD-AR greater than 0.4 is a significant and independent prognostic factor for relapse in pediatric AML...
- Outcomes in childhood AML in the absence of transplantation in first remission--Children's Cancer Group (CCG) studies 2891 and CCG 213Sharon M Castellino
ETSU Quillen College of Medicine, Johnson City, Tennessee, USA
Pediatr Blood Cancer 50:9-16. 2008..The majority of childhood acute myeloid leukemia (AML) patients lack a matched-related bone marrow transplant (BMT) donor in first remission...
- Obesity and outcome in pediatric acute lymphoblastic leukemiaAnna M Butturini
Childrens Hospital Los Angeles and Keck School of Medicine, University of Southern California, Los Angeles, CA 90027, USA
J Clin Oncol 25:2063-9. 2007..To evaluate the effect of obesity (defined as a body mass index > 95th percentile for age and sex at diagnosis) on outcome of pediatric acute lymphoblastic leukemia (ALL)...
- Microbiologically documented infections and infection-related mortality in children with acute myeloid leukemiaLillian Sung
Division of Haematology Oncology, Hospital for Sick Children, Toronto, ON, Canada
Blood 110:3532-9. 2007..Thus, age, ethnicity, and BMI were important contributors to IRM. Fungi and Gram-positive cocci were the most common organisms associated with IRM and, in particular, Aspergillus species was the largest contributor to infectious deaths...
- Risk factors and therapy for isolated central nervous system relapse of pediatric acute myeloid leukemiaDonna L Johnston
Division of Hematology Oncology, Children s Hospital of Eastern Ontario, Ottawa, Ontario, Canada
J Clin Oncol 23:9172-8. 2005..CNS relapse of pediatric acute myeloid leukemia (AML) is an infrequent occurrence. This review examines the risk factors and therapy used for patients with an isolated CNS relapse...
- Impact of granulocyte colony-stimulating factor use during induction for acute myelogenous leukemia in children: a report from the Children's Cancer GroupTodd A Alonzo
Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
J Pediatr Hematol Oncol 24:627-35. 2002....
- Obesity in pediatric oncologyPaul C Rogers
Children s and Women s Hospital and University of British Columbia, Vancouver, British Columbia, Canada
Pediatr Blood Cancer 45:881-91. 2005....
- Allogeneic bone marrow transplantation for children with acute myelocytic leukemia in first remission demonstrates a role for graft versus leukemia in the maintenance of disease-free survivalSteven Neudorf
American Family Life Assurance Company AFLAC Cancer Center, Emory University Children s Healthcare, Atlanta, GA, USA
Blood 103:3655-61. 2004..014) were associated with improved relapse-free survival (RFS). Our results show that children older than 10 years are at higher risk for developing severe GVHD; acute GVHD is associated with favorable RFS...
- Immunophenotypic evidence of leukemia after induction therapy predicts relapse: results from a prospective Children's Cancer Group study of 252 patients with acute myeloid leukemiaEric L Sievers
Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA the Department of Pediatrics, University of Washington, Seattle, WA 98109, USA
Blood 101:3398-406. 2003..Among patients in whom a marrow sample was available for analysis at the end of consolidation therapy, overall survival at 3 years was 41% versus 69% for patients with and without occult leukemia, respectively (P =.0058)...
- Low NAD(P)H:quinone oxidoreductase activity is associated with increased risk of leukemia with MLL translocations in infants and childrenMartyn T Smith
Division of Environmental Health Sciences, School of Public Health, University of California, Berkeley 94720 7360, USA
Blood 100:4590-3. 2002..The inactivating NQO1 polymorphism is associated with an increased risk of de novo leukemia with MLL translocations in infants and children...
- Structural and numerical variation of FLT3/ITD in pediatric AMLSoheil Meshinchi
Clinical Research Division, Fred Hutchinson Cancer Research Center, University of Washington Medical Center, Seattle, USA
Blood 111:4930-3. 2008..035), while the presence of more than 1 ITD was not clinically significant. Physical characteristics including the length of FLT3/ITD may influence FLT3 activation state by altering its structure and may impact response to therapy...
- Extramedullary leukemia in children with newly diagnosed acute myeloid leukemia: a report from the Children's Cancer GroupKathryn E Dusenbery
University of Minnesota, Minneapolis, USA
J Pediatr Hematol Oncol 25:760-8. 2003..To describe features of patients with acute myeloid leukemia presenting with extramedullary leukemic tumors (EML)...
- Progenitor cell involvement is predictive of response to induction chemotherapy in paediatric acute myeloid leukaemiaDonna L Johnston
Fred Hutchinson Cancer Research Center, Seattle, WA, USA
Br J Haematol 123:431-5. 2003..However, five of six evaluable patients with colonies negative for monosomy 7 entered remission. These data support the hypothesis that leukaemic involvement of early progenitor cells affects the response to induction chemotherapy...
- A pharmacoeconomic analysis of pegaspargase versus native Escherichia coli L-asparaginase for the treatment of children with standard-risk, acute lymphoblastic leukemia: the Children's Cancer Group study (CCG-1962)Helen A Kurre
Clinical Services Administration, Children s Hospital and Regional Medical Center, Seattle, Washington, USA
J Pediatr Hematol Oncol 24:175-81. 2002..a newer chemotherapeutic agent used for treating acute lymphoblastic leukemia, with native Escherichia coli L-asparaginase in induction, delayed intensification 1 and delayed intensification 2...
- Minimally differentiated acute myeloid leukemia (FAB AML-M0) is associated with an adverse outcome in children: a report from the Children's Oncology Group, studies CCG-2891 and CCG-2961Draga Barbaric
Division of Hematology Oncology BMT, BC s Children s Hospital, Vancouver, BC, Canada
Blood 109:2314-21. 2007..There was no significant outcome difference between DS-associated AML-M0 and non-M0 children. This study suggests that intensively treated non-DS-associated AML-M0 children have an inferior outcome compared with children with non-M0 AML...
- XPD Lys751Gln polymorphism in the etiology and outcome of childhood acute myeloid leukemia: a Children's Oncology Group reportParinda A Mehta
Cincinnati Children s Hospital and Medical Center, 3333 Burnet Ave, Cincinnati, OH 45229, USA
Blood 107:39-45. 2006..These data, representing the only data in pediatric AML, suggest that XPD genotype does not affect the etiology or outcome of childhood AML...
- Prospective study of 90 children requiring treatment for juvenile myelomonocytic leukemia or myelodysplastic syndrome: a report from the Children's Cancer GroupWilliam G Woods
AFLAC Cancer Center, Emory University Children s Healthcare, Atlanta, GA, USA
J Clin Oncol 20:434-40. 2002..We report the first large prospective study of children with myelodysplastic syndrome (MDS) and juvenile myelomonocytic leukemia (JMML) treated in a uniform fashion on Children's Cancer Group protocol 2891...